Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.
Identifieur interne : 002D24 ( PubMed/Curation ); précédent : 002D23; suivant : 002D25Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.
Auteurs : Silke Tribius [Allemagne] ; Stefanie Kronemann ; Yasemin Kilic ; Ursula Schroeder ; Samer Hakim ; Steven E. Schild ; Dirk RadesSource :
- Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [ 1439-099X ] ; 2009.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Analyse de survie, Association thérapeutique, Calendrier d'administration des médicaments, Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (mortalité), Carcinome épidermoïde (radiothérapie), Carcinome épidermoïde (traitement médicamenteux), Cisplatine (administration et posologie), Cisplatine (effets indésirables), Femelle, Fluorouracil (administration et posologie), Fluorouracil (effets indésirables), Fractionnement de la dose d'irradiation, Humains, Lésions radio-induites (étiologie), Mâle, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Stade de la tumeur, Survie sans rechute, Traitement médicamenteux adjuvant, Tumeurs oto-rhino-laryngologiques (anatomopathologie), Tumeurs oto-rhino-laryngologiques (mortalité), Tumeurs oto-rhino-laryngologiques (radiothérapie), Tumeurs oto-rhino-laryngologiques (traitement médicamenteux), Études de suivi, Études rétrospectives.
- MESH :
- administration et posologie : Cisplatine, Fluorouracil.
- anatomopathologie : Carcinome épidermoïde, Tumeurs oto-rhino-laryngologiques.
- effets indésirables : Cisplatine, Fluorouracil, Protocoles de polychimiothérapie antinéoplasique.
- mortalité : Carcinome épidermoïde, Tumeurs oto-rhino-laryngologiques.
- radiothérapie : Carcinome épidermoïde, Tumeurs oto-rhino-laryngologiques.
- traitement médicamenteux : Carcinome épidermoïde, Tumeurs oto-rhino-laryngologiques.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- étiologie : Lésions radio-induites.
- Adulte d'âge moyen, Analyse de survie, Association thérapeutique, Calendrier d'administration des médicaments, Femelle, Fractionnement de la dose d'irradiation, Humains, Mâle, Stade de la tumeur, Survie sans rechute, Traitement médicamenteux adjuvant, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (mortality), Carcinoma, Squamous Cell (pathology), Carcinoma, Squamous Cell (radiotherapy), Chemotherapy, Adjuvant, Cisplatin (administration & dosage), Cisplatin (adverse effects), Combined Modality Therapy, Disease-Free Survival, Dose Fractionation, Drug Administration Schedule, Female, Fluorouracil (administration & dosage), Fluorouracil (adverse effects), Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Otorhinolaryngologic Neoplasms (drug therapy), Otorhinolaryngologic Neoplasms (mortality), Otorhinolaryngologic Neoplasms (pathology), Otorhinolaryngologic Neoplasms (radiotherapy), Radiation Injuries (etiology), Retrospective Studies, Survival Analysis.
- MESH :
- chemical , administration & dosage : Cisplatin, Fluorouracil.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Fluorouracil.
- drug therapy : Carcinoma, Squamous Cell, Otorhinolaryngologic Neoplasms.
- etiology : Radiation Injuries.
- mortality : Carcinoma, Squamous Cell, Otorhinolaryngologic Neoplasms.
- pathology : Carcinoma, Squamous Cell, Otorhinolaryngologic Neoplasms.
- radiotherapy : Carcinoma, Squamous Cell, Otorhinolaryngologic Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival, Dose Fractionation, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Survival Analysis.
Abstract
The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN).
DOI: 10.1007/s00066-009-1992-x
PubMed: 19806333
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D24
Links to Exploration step
pubmed:19806333Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.</title><author><name sortKey="Tribius, Silke" sort="Tribius, Silke" uniqKey="Tribius S" first="Silke" last="Tribius">Silke Tribius</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Kronemann, Stefanie" sort="Kronemann, Stefanie" uniqKey="Kronemann S" first="Stefanie" last="Kronemann">Stefanie Kronemann</name></author><author><name sortKey="Kilic, Yasemin" sort="Kilic, Yasemin" uniqKey="Kilic Y" first="Yasemin" last="Kilic">Yasemin Kilic</name></author><author><name sortKey="Schroeder, Ursula" sort="Schroeder, Ursula" uniqKey="Schroeder U" first="Ursula" last="Schroeder">Ursula Schroeder</name></author><author><name sortKey="Hakim, Samer" sort="Hakim, Samer" uniqKey="Hakim S" first="Samer" last="Hakim">Samer Hakim</name></author><author><name sortKey="Schild, Steven E" sort="Schild, Steven E" uniqKey="Schild S" first="Steven E" last="Schild">Steven E. Schild</name></author><author><name sortKey="Rades, Dirk" sort="Rades, Dirk" uniqKey="Rades D" first="Dirk" last="Rades">Dirk Rades</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19806333</idno><idno type="pmid">19806333</idno><idno type="doi">10.1007/s00066-009-1992-x</idno><idno type="wicri:Area/PubMed/Corpus">002D24</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D24</idno><idno type="wicri:Area/PubMed/Curation">002D24</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.</title><author><name sortKey="Tribius, Silke" sort="Tribius, Silke" uniqKey="Tribius S" first="Silke" last="Tribius">Silke Tribius</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Kronemann, Stefanie" sort="Kronemann, Stefanie" uniqKey="Kronemann S" first="Stefanie" last="Kronemann">Stefanie Kronemann</name></author><author><name sortKey="Kilic, Yasemin" sort="Kilic, Yasemin" uniqKey="Kilic Y" first="Yasemin" last="Kilic">Yasemin Kilic</name></author><author><name sortKey="Schroeder, Ursula" sort="Schroeder, Ursula" uniqKey="Schroeder U" first="Ursula" last="Schroeder">Ursula Schroeder</name></author><author><name sortKey="Hakim, Samer" sort="Hakim, Samer" uniqKey="Hakim S" first="Samer" last="Hakim">Samer Hakim</name></author><author><name sortKey="Schild, Steven E" sort="Schild, Steven E" uniqKey="Schild S" first="Steven E" last="Schild">Steven E. Schild</name></author><author><name sortKey="Rades, Dirk" sort="Rades, Dirk" uniqKey="Rades D" first="Dirk" last="Rades">Dirk Rades</name></author></analytic><series><title level="j">Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]</title><idno type="eISSN">1439-099X</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Carcinoma, Squamous Cell (drug therapy)</term><term>Carcinoma, Squamous Cell (mortality)</term><term>Carcinoma, Squamous Cell (pathology)</term><term>Carcinoma, Squamous Cell (radiotherapy)</term><term>Chemotherapy, Adjuvant</term><term>Cisplatin (administration & dosage)</term><term>Cisplatin (adverse effects)</term><term>Combined Modality Therapy</term><term>Disease-Free Survival</term><term>Dose Fractionation</term><term>Drug Administration Schedule</term><term>Female</term><term>Fluorouracil (administration & dosage)</term><term>Fluorouracil (adverse effects)</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Otorhinolaryngologic Neoplasms (drug therapy)</term><term>Otorhinolaryngologic Neoplasms (mortality)</term><term>Otorhinolaryngologic Neoplasms (pathology)</term><term>Otorhinolaryngologic Neoplasms (radiotherapy)</term><term>Radiation Injuries (etiology)</term><term>Retrospective Studies</term><term>Survival Analysis</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Association thérapeutique</term><term>Calendrier d'administration des médicaments</term><term>Carcinome épidermoïde (anatomopathologie)</term><term>Carcinome épidermoïde (mortalité)</term><term>Carcinome épidermoïde (radiothérapie)</term><term>Carcinome épidermoïde (traitement médicamenteux)</term><term>Cisplatine (administration et posologie)</term><term>Cisplatine (effets indésirables)</term><term>Femelle</term><term>Fluorouracil (administration et posologie)</term><term>Fluorouracil (effets indésirables)</term><term>Fractionnement de la dose d'irradiation</term><term>Humains</term><term>Lésions radio-induites (étiologie)</term><term>Mâle</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Stade de la tumeur</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs oto-rhino-laryngologiques (anatomopathologie)</term><term>Tumeurs oto-rhino-laryngologiques (mortalité)</term><term>Tumeurs oto-rhino-laryngologiques (radiothérapie)</term><term>Tumeurs oto-rhino-laryngologiques (traitement médicamenteux)</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cisplatin</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cisplatine</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Cisplatin</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs oto-rhino-laryngologiques</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Otorhinolaryngologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Cisplatine</term><term>Fluorouracil</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Radiation Injuries</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Otorhinolaryngologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs oto-rhino-laryngologiques</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Otorhinolaryngologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Otorhinolaryngologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs oto-rhino-laryngologiques</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs oto-rhino-laryngologiques</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lésions radio-induites</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chemotherapy, Adjuvant</term><term>Combined Modality Therapy</term><term>Disease-Free Survival</term><term>Dose Fractionation</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Retrospective Studies</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Association thérapeutique</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Fractionnement de la dose d'irradiation</term><term>Humains</term><term>Mâle</term><term>Stade de la tumeur</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19806333</PMID><DateCreated><Year>2009</Year><Month>10</Month><Day>06</Day></DateCreated><DateCompleted><Year>2009</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-099X</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]</Title><ISOAbbreviation>Strahlenther Onkol</ISOAbbreviation></Journal><ArticleTitle>Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.</ArticleTitle><Pagination><MedlinePgn>675-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00066-009-1992-x</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Concurrent chemotherapy consisted of either two courses cisplatin (20 mg/m(2)/d1-5 + 29-33; n = 54) or two courses cisplatin (20 mg/m(2)/d1-5 + 29-33) + 5-fluorouracil (5-FU; 600 mg/m(2)/d1-5 + 29-33; n = 74).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At least one grade 3 toxicity occurred in 25 of 54 patients (46%) receiving cisplatin alone and in 52 of 74 patients (70%) receiving cisplatin + 5-FU. The latter regimen was particularly associated with increased rates of mucositis (p = 0.027) and acute skin toxicity (p = 0.001). Seven of 54 (13%) and 20 of 74 patients (27%) received only one chemotherapy course due to treatment-related acute toxicity. Late toxicity in terms of xerostomia, neck fibrosis, skin toxicity, and lymphedema was not significantly different. The 2-year locoregional control rates were 67% after cisplatin alone and 52% after cisplatin + 5-FU (p = 0.35). The metastases-free survival rates were 79% and 69%, respectively (p = 0.65), and the overall survival rates 70% and 51%, respectively (p = 0.10). On multivariate analysis, outcome was significantly associated with performance status, T-category, N-category, hemoglobin level prior to radiotherapy, and radiotherapy break > 1 week.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Two courses of fractionated cisplatin (20 mg/m(2)/day) alone appear preferable, as this regimen resulted in similar outcome and late toxicity as two courses of cisplatin + 5-FU, but in significantly less acute toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tribius</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronemann</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kilic</LastName><ForeName>Yasemin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Ursula</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Hakim</LastName><ForeName>Samer</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schild</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Rades</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Strahlenther Onkol</MedlineTA><NlmUniqueID>8603469</NlmUniqueID><ISSNLinking>0179-7158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019583" MajorTopicYN="N">Dose Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010039" MajorTopicYN="N">Otorhinolaryngologic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011832" MajorTopicYN="N">Radiation Injuries</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19806333</ArticleId><ArticleId IdType="doi">10.1007/s00066-009-1992-x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002D24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19806333
|texte= Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19806333" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |